These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 1398280

  • 1. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL, Bertolino G, Noris P, Ascari E.
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [Abstract] [Full Text] [Related]

  • 2. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP.
    N Engl J Med; 1988 May 19; 318(20):1292-4. PubMed ID: 3362187
    [Abstract] [Full Text] [Related]

  • 3. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
    Trapp OM, Beykirch MK, Petrides PE.
    Blood Cells Mol Dis; 1998 Mar 19; 24(1):9-13. PubMed ID: 9516377
    [Abstract] [Full Text] [Related]

  • 4. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
    Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F.
    Haematologica; 1992 Mar 19; 77(4):315-7. PubMed ID: 1427441
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J.
    Haematologica; 2004 May 19; 89(5):520-7. PubMed ID: 15136214
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI, Vassallu PS, Heller P, Molinas FC.
    Medicina (B Aires); 2002 May 19; 62(3):231-6. PubMed ID: 12150005
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group.
    Leuk Res; 2005 May 19; 29(5):481-91. PubMed ID: 15755500
    [Abstract] [Full Text] [Related]

  • 16. [Anagrelide in primary thrombocythemia].
    Knutsen H, Hysing J.
    Tidsskr Nor Laegeforen; 2001 May 10; 121(12):1478-82. PubMed ID: 11449771
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan 10; 92(1):69-76. PubMed ID: 1731512
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.